BioCatalyst

Futibatinib, Pembrolizumab, Cisplatin, 5-FU — catalyst calendar

1 verified catalyst event(s) referencing Futibatinib, Pembrolizumab, Cisplatin, 5-FU, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-10-01
in 11d
ESTIMATED
 READOUT
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in
Phase 2 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma
 Taiho Oncology, Inc. Futibatinib, Pembrolizumab, Cisplatin, 5 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.